ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

ENESTfreedom and ENESTop are evaluating TFR (ie, tyrosine kinase inhibitor [TKI] cessation without losing response) after frontline and second-line nilotinib, respectively.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jerald Radich, Fran çois-Xavier Mahon, Andreas Hochhaus, Timothy Hughes, Sikander Ailawadhi, Jeffrey Lipton, Prashanth Gopalakrishna, Rafik Fellague-Chebra, Weiping Deng, Sandip Acharya, Giuseppe Saglio Source Type: research